Recent ENTO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/14/2025 08:15:32 PM
- Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend] • Edgar (US Regulatory) • 04/09/2025 09:21:10 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/01/2025 09:12:54 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2025 03:06:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2025 08:06:04 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2025 09:05:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2025 09:25:26 PM
- Entero Therapeutics Appoints Richard Paolone as CEO • GlobeNewswire Inc. • 02/14/2025 09:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2025 10:02:13 PM
- Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members • GlobeNewswire Inc. • 02/07/2025 08:22:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2025 09:31:41 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 09:18:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2024 10:00:44 PM
- Entero Therapeutics CEO James Sapirstein to Moderate the 2024 BioFlorida Annual Innovation Conference CEO Forum • GlobeNewswire Inc. • 11/14/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2024 12:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2024 12:00:14 PM
- Entero Therapeutics Announces Proposed Reverse Merger with Journey Therapeutics, A Clinical Stage, First-in-Class, Next-Generation ADC-rivalling Nano-immunoconjugates Biopharmaceutical Company • GlobeNewswire Inc. • 11/13/2024 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/21/2024 11:31:25 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/10/2024 09:00:12 PM
- Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings • GlobeNewswire Inc. • 09/10/2024 11:00:00 AM
- Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q • GlobeNewswire Inc. • 08/23/2024 09:00:00 PM
- Entero Therapeutics’ Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Entero Therapeutics Announces Peer-Reviewed Publication Unveiling Novel Algorithm for Measuring Intestinal Damage in Celiac Disease • GlobeNewswire Inc. • 06/27/2024 10:00:00 AM
HealthLynked Welcomes Anthony Scuilla as Sales Consultant to Drive Strategic Partnerships with Insurance Providers • HLYK • Apr 14, 2025 8:00 AM
Glidelogic Corp. Partners with Sunwah Global Youth Innovation Center • GDLG • Apr 10, 2025 4:00 PM
Opus Holdings, Inc. (OTC: CATV) Reports Nearly $500K in Q4 Revenue, eliminates $830K in Debt, and Appoints Visionary CEO to Lead Bold Transformation • CATV • Apr 10, 2025 9:34 AM
AI-Powered Service Robots Redefine Hospitality as Industry Innovators Lead the Charge • NGTF • Apr 10, 2025 9:00 AM
UAV Corp Powers Forward: T-Wing Nears Completion, Global Momentum Accelerates with Saudi Arabia in Sight • UMAV • Apr 10, 2025 8:30 AM
UAV Corp and Genetic Networks Announce Strategic Collaboration to Combat Biohazards with Cutting-Edge Technology, Genetic Networks Signs MOU with UMAV • FITY • Apr 9, 2025 9:00 AM